ATE459646T1 - Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist - Google Patents

Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Info

Publication number
ATE459646T1
ATE459646T1 AT02775586T AT02775586T ATE459646T1 AT E459646 T1 ATE459646 T1 AT E459646T1 AT 02775586 T AT02775586 T AT 02775586T AT 02775586 T AT02775586 T AT 02775586T AT E459646 T1 ATE459646 T1 AT E459646T1
Authority
AT
Austria
Prior art keywords
deletion
exon
detection
diagnostic method
csf
Prior art date
Application number
AT02775586T
Other languages
English (en)
Inventor
Sang-Yup Lee
Ki-Jun Jeong
Hyun-Cheol Chung
Nae-Choon Yoo
Ki-Chang Keum
Won-Min Yoo
Original Assignee
Medigenes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigenes filed Critical Medigenes
Application granted granted Critical
Publication of ATE459646T1 publication Critical patent/ATE459646T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT02775586T 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist ATE459646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010060826 2001-09-28
PCT/KR2002/001825 WO2003027288A1 (en) 2001-09-28 2002-09-28 Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3

Publications (1)

Publication Number Publication Date
ATE459646T1 true ATE459646T1 (de) 2010-03-15

Family

ID=19714831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775586T ATE459646T1 (de) 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Country Status (9)

Country Link
US (10) US20040247562A1 (de)
EP (1) EP1446485B1 (de)
JP (1) JP4413611B2 (de)
KR (2) KR100523328B1 (de)
CN (1) CN100491527C (de)
AT (1) ATE459646T1 (de)
AU (1) AU2002343900B2 (de)
DE (1) DE60235568D1 (de)
WO (1) WO2003027288A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067170A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
KR20070019524A (ko) * 2005-08-12 2007-02-15 메디제네스(주) 암 진단 마커 및 방법
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
EP2542574B1 (de) 2010-03-04 2017-08-09 Pfenex Inc. Verfahren zur herstellung eines löslichen und rekombinanten interferonproteins ohne denaturierung
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
EP0791061A4 (de) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Tiere mit gezielter genunterbrechung
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
KR100365482B1 (ko) 1999-12-28 2002-12-26 철 근 김 종양 억제 유전자의 프라이머쌍을 포함하는 암 진단용 벡터

Also Published As

Publication number Publication date
US20050244856A1 (en) 2005-11-03
WO2003027288A9 (en) 2003-06-05
US20100286381A1 (en) 2010-11-11
CN1561395A (zh) 2005-01-05
US20050158810A1 (en) 2005-07-21
US20050170416A1 (en) 2005-08-04
WO2003027288A1 (en) 2003-04-03
US20050266430A1 (en) 2005-12-01
US20040247562A1 (en) 2004-12-09
AU2002343900B2 (en) 2007-04-26
CN100491527C (zh) 2009-05-27
JP4413611B2 (ja) 2010-02-10
EP1446485B1 (de) 2010-03-03
JP2005503810A (ja) 2005-02-10
US20140005365A1 (en) 2014-01-02
EP1446485A4 (de) 2005-05-25
US20120322684A1 (en) 2012-12-20
KR100523328B1 (ko) 2005-10-24
EP1446485A1 (de) 2004-08-18
KR20050098821A (ko) 2005-10-12
US20120329078A1 (en) 2012-12-27
US20050170417A1 (en) 2005-08-04
US8324363B2 (en) 2012-12-04
DE60235568D1 (de) 2010-04-15
KR20030027870A (ko) 2003-04-07
KR100716014B1 (ko) 2007-05-08

Similar Documents

Publication Publication Date Title
Méndez et al. Transcriptional expression profiles of oral squamous cell carcinomas
US20230146253A1 (en) Methods related to bronchial premalignant lesion severity and progression
Baba et al. A novel allelic variant of serum amyloic A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA–amyloidosis
AU722819B2 (en) Diagnosis of disease state using mRNA profiles
DE69521813D1 (de) Verfahrens und testsätze zur diagnose periodentahlkrankheiten und zur vorhersage des risikos der progression davon
ATE350486T1 (de) Durch mechanischen stress induzierte gene, deren expressionsprodukte und deren verwendung.
RU2015113089A (ru) Анализ протеома слюны на биомаркеры гингивита и периодонтита с использованием ft-icr-ms/ms
DE60239089D1 (de) Verfahren zur Diagnose von Krebserkrankungen durch Messung der TIMP-1-Glycosylationsveränderungen im Zusammenhang mit der Tumorgenese und Metastasen
DK0757723T3 (da) Genetiske ændringer, der korrelerer med lungecarcinoma
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
ATE459646T1 (de) Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist
DE69226775D1 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
DE60334408D1 (de) Nsäuren
ATE440138T1 (de) Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen
ES2700790T3 (es) Marcador epigenético para la identificación de linfocitos T il17 positivos en muestras complejas
DE602004024300D1 (de) Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs
KR102928508B1 (ko) 대장암 재발 예측용 바이오 마커
KR102893524B1 (ko) 간질환 환자에서 간 섬유화 진행의 예후를 예측하기 위한 분석방법
Caetano et al. Mapping the Spatial Dynamics of the Human Oral Mucosa in Chronic Inflammatory Disease
ATE369426T1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
WO2003062398A3 (en) NEW TUMOR SUPPRESSOR GENE, p28ING5

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties